Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 5/2016

01.05.2016 | Prostate Cancer (A Kibel, Section Editor)

Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy

verfasst von: Eugene J. Pietzak, James A. Eastham

Erschienen in: Current Urology Reports | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Multimodal strategies combining local and systemic therapy offer the greatest chance of cure for many with men with high-risk prostate cancer who may harbor occult metastatic disease. However, no systemic therapy combined with radical prostatectomy has proven beneficial. This was in part due to a lack of effective systemic agents; however, there have been several advancements in the metastatic and castrate-resistant prostate cancer that might prove beneficial if given earlier in the natural history of the disease. For example, novel hormonal agents have recently been approved for castration-resistant prostate cancer with some early phase II neoadjuvant showing promise. Additionally, combination therapy with docetaxel-based chemohormonal has demonstrated a profound survival benefit in metastatic hormone-naïve patients and might have a role in eliminating pre-existing ADT-resistant tumor cells in the neoadjuvant setting. The Cancer and Leukemia Group B (CALGB)/Alliance 90203 trial has finished accrual and should answer the question as to whether neoadjuvant docetaxel-based chemohormonal therapy provides an advantage over prostatectomy alone. There are also several promising targeted agents and immunotherapies under investigation in phase I/II trials with the potential to provide benefit in the neoadjuvant setting.
Literatur
1.
Bach C et al. The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol. 2014;11(6):342–51.CrossRefPubMed
2.
Yossepowitch O et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–9.CrossRefPubMedPubMedCentral
3.••
Chang AJ et al. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23. This excellent review provides an overview of the current state of prostate cancer management with a focus on optimal design for future studies. CrossRefPubMedPubMedCentral
4.
Mitchell JA et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173(4):1126–31.CrossRefPubMed
5.
Cha EK, Eastham JA. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. Urol Oncol. 2015;33(5):217–25.CrossRefPubMed
6.
Widmark A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–8.CrossRefPubMed
7.
Mason MD et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143–50.CrossRefPubMedPubMedCentral
8.
Bolla M et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27.CrossRefPubMed
9.
Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol. 2003;21(21):3972–8.CrossRefPubMed
10.
11.
Garzotto M, Hung AY. Advances in the multimodality management of high-risk prostate cancer. Surg Oncol Clin N Am. 2013;22(2):375–94.CrossRefPubMed
12.
Bill-Axelson A et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.CrossRefPubMed
13.
Silberstein JL et al. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer. 2011;117(21):4855–60.CrossRefPubMedPubMedCentral
14.
15.
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.CrossRefPubMed
16.
Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case–control study. J Urol. 2015;193(3):832–8.CrossRefPubMed
17.
Thalgott M et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;7:20.CrossRefPubMedPubMedCentral
18.
Williams SB, et al. Neoadjuvant systemic therapy before radical prostatectomy in high-risk prostate cancer does not increase surgical morbidity: contemporary results using the Clavien system. Clin Genitourin Cancer. 2015.
19.
Stephenson AJ et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27(26):4300–5.CrossRefPubMedPubMedCentral
20.
Vallet BS. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Del Med J. 1944;16:18–20.
21.
Soloway MS et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112–6.CrossRefPubMed
22.
Shelley MD et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17.CrossRefPubMed
23.
Chi KN et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–70. discussion 570.CrossRefPubMed
24.
Joung JY et al. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer. BMC Urol. 2015;15:82.CrossRefPubMedPubMedCentral
25.
Gleave ME et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166(2):500–6. discussion 506–7.CrossRefPubMed
26.
Gleave ME, Goldenberg SL, Chin JL. Randomized comparative study of 3 versus 8-months of neoadjuvant hormonal therapy prior to radical prostatectomy(3 year PSA recurrence rates). J Urol, 2003; 169(179): p. (Abstract 690).
27.
Mohler JL et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12(5):686–718.PubMed
28.
Mostaghel EA et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033–41.CrossRefPubMed
29.
Small EJ. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? J Clin Oncol. 2014;32(33):3689–91.CrossRefPubMed
30.
Spratt DE et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res. 2015;75(22):4688–96.CrossRefPubMed
31.
32.
33.
34.••
Taplin ME et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705–15. This phase II trial demostrates the potential of novel hormonal agents in the neoadjuvant setting. Phase III trials are underway and much anticipated. CrossRefPubMedPubMedCentral
35.
Eigl BJ, Gleave ME, Chi KN. The future of systemic therapies for localised prostate cancer. Clin Oncol (R Coll Radiol). 2013;25(8):506–13.CrossRef
36.
37.
Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMed
38.
Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMed
39.
Eigl BJ et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005;11(13):4905–11.CrossRefPubMed
40.
41.
Santer FR, Erb HH, McNeill RV. Therapy escape mechanisms in the malignant prostate. Semin Cancer Biol. 2015;35:133–44.CrossRefPubMed
42.
Konety BR et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol. 2004;171(2 Pt 1):709–13.CrossRefPubMed
43.
Silberstein JL et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. BJU Int. 2015;116(1):50–6.CrossRefPubMedPubMedCentral
44.
Prayer-Galetti T et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–80.CrossRefPubMed
45.
Sella A et al. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–7.CrossRefPubMed
46.
Mellado B et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–52.CrossRefPubMedPubMedCentral
47.
Womble PR et al. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol. 2011;186(3):882–7.CrossRefPubMed
48.
Narita S et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1.CrossRefPubMedPubMedCentral
49.
Zurita AJ et al. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015;18(3):276–80.CrossRefPubMed
50.
Tzelepi V et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.CrossRefPubMedPubMedCentral
51.••
Sweeney CJ et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. This landmark trial demonstrated a substantial survival advantage for docetaxel-based chemohormonal therapy in metastatic hormone-sensitive prostate cancer.CrossRefPubMedPubMedCentral
52.
James ND. et al., Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol. 2015; 33: p. (suppl; abstr 5001).
53.
Gravis G et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.CrossRefPubMed
54.••
Fizazi K et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787–94. This recent trial demonstrated a significant improvement in the composite primary endpoint “relapse-free survival” for docetaxel-based chemohormonal therapy as neoadjuvant therapy in mostly radiation treated patients. CrossRefPubMed
55.
Fizazi K et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer. 2012;48(2):209–17.CrossRefPubMed
56.
Eastham JA et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62 Suppl 1:55–62.CrossRefPubMed
57.
Lou DY, L Fong. Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor. Urol Oncol, 2014.
58.
Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat Rev Drug Discov. 2013;12(8):569.CrossRefPubMed
59.
60.
61.
Cancer Genome Atlas Research Network. Cancer Genome Atlas Research, The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011–25.CrossRef
62.
Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.CrossRefPubMed
63.
Barnett CM et al. Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res. 2014;20(5):1306–12.CrossRefPubMedPubMedCentral
64.
Rajpar S, et al. A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12). J Clin Oncol. 2014; 32(5s): p. (suppl; abstr 5063).
Metadaten
Titel
Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
verfasst von
Eugene J. Pietzak
James A. Eastham
Publikationsdatum
01.05.2016
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 5/2016
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0592-4

Weitere Artikel der Ausgabe 5/2016

Current Urology Reports 5/2016 Zur Ausgabe

Minimally Invasive Surgery (T Guzzo, Section Editor)

Selective Arterial Clamping Versus Hilar Clamping for Minimally Invasive Partial Nephrectomy

Minimally Invasive Surgery (T Guzzo, Section Editor)

Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes

Urothelial Cancer (A Sagalowsky, Section Editor)

Complications Following Radical Nephroureterectomy

Minimally Invasive Surgery (T Guzzo, Section Editor)

Minimally Invasive Techniques for the Management of Adult UPJ Obstruction

Urothelial Cancer (A Sagalowsky, Section Editor)

Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise